Executive Summary / Key Takeaways
-
Portfolio Purification as Margin Medicine: Surgery Partners is actively divesting larger surgical hospitals that fall outside its core short-stay strategy, exemplified by the Baylor Scott & White joint venture, which will improve earnings contribution despite lower ownership—a critical move to reduce leverage from 4.2x toward management's 3x target while focusing capital on higher-margin ASCs.
-
Physician Transition Risk Materializes: Q4 2025's EBITDA shortfall was concentrated in just three surgical hospital markets where experienced physicians departed and new recruits brought unfavorable Medicare-heavy payer mixes, exposing the business model's acute vulnerability to physician retention and recruitment quality—a risk that is identifiable and addressable but will pressure 2026 results.
-
De Novo Growth Engine Requires Patience: The company opened eight de novo facilities in 2025, heavily weighted toward high-acuity orthopedics, but these facilities take 12-18 months to build and another year to reach breakeven, meaning the $182 million deployed in 2025 acquisitions won't drive meaningful EBITDA until 2027, creating a timing mismatch with near-term margin pressure.
-
Interest Rate Headwind Intensifies: The expiration of $1.2 billion in interest rate swaps in Q1 2025 created a 220 basis point cash flow headwind for the last nine months of 2025, with effective interest rates jumping to 7.4% in Q2, directly consuming $23 million more in interest payments year-over-year and limiting financial flexibility during the portfolio transition.
-
Valuation Reflects Turnaround Execution Risk: Trading at 8.2x EV/EBITDA and 0.48x Price/Sales with negative net margins, SGRY trades at a discount to HCA Healthcare (HCA) (9.9x EV/EBITDA) and Tenet Healthcare (THC) (6.1x EV/EBITDA) but requires successful execution of its portfolio optimization and physician maturation to justify any multiple expansion, making it a show-me story with 2026 guidance of "at least $530 million" EBITDA offering minimal growth visibility.
Setting the Scene: The Last Independent ASC Pure-Play
Surgery Partners, founded in 2004, has carved out a distinctive niche as the last independent freestanding short-stay surgical company in the country. This positioning is significant because it places the company at the center of healthcare's most powerful cost containment trend: the migration of surgical procedures from expensive hospital settings to lower-cost ambulatory surgery centers (ASCs). The company operates 176 surgical facilities across 30 states, with 157 ASCs and 19 licensed surgical hospitals generating $3.31 billion in annual revenue. Unlike integrated health systems like HCA Healthcare or Tenet Healthcare, Surgery Partners doesn't operate full-service hospitals, giving it a structural cost advantage that payers increasingly favor.
The business model is straightforward but operationally complex: Surgery Partners partners with physicians who maintain ownership stakes in facilities, aligning incentives while the company provides management, administrative services, and capital for expansion. This physician-centric structure creates a powerful referral engine but also introduces the key vulnerability exposed in 2025—when physicians leave, volumes and payer mix can deteriorate rapidly. The company makes money through facility fees charged to patients and insurers, with 52.3% of revenue from private insurance, 42.8% from government payers, and the remainder from self-pay and other sources. The strategic imperative is shifting case mix toward higher-acuity , higher-reimbursement procedures like orthopedics and total joint replacements, which now represent 40.7% of cases and grew 26% in Q2 2025.
Industry dynamics provide a strong tailwind. CMS (Centers for Medicare & Medicaid Services) is actively driving procedures to ASCs, proposing to add 276 procedures to the ASC covered list in 2026 and phasing out the inpatient-only list over three years. This regulatory shift expands Surgery Partners' addressable market from the current $40 billion short-stay surgical market toward a potential $150 billion as more complex procedures become eligible for outpatient settings. The aging population and technological advances enabling minimally invasive surgery further accelerate this migration, creating a 6.25% CAGR growth trajectory for the ASC sector through 2030. Against this backdrop, Surgery Partners' pure-play focus becomes a strategic asset, allowing faster adaptation than hospital-centric competitors burdened by legacy inpatient infrastructure.
Technology, Products, and Strategic Differentiation: The De Novo Advantage
Surgery Partners' core technology isn't software but rather its integrated outpatient delivery model and physician partnership network. The company has placed 74 surgical robots in service across its facilities, adding six in 2025 alone, enabling physicians to perform increasingly complex procedures in ASC settings. This robotic capability directly supports the shift to higher-acuity orthopedics, where total joint procedures grew 22% in Q1 2025. Unlike traditional hospitals that deploy robotics across multiple service lines, Surgery Partners concentrates this capital in purpose-built orthopedic facilities, maximizing utilization and return on investment.
The de novo development program represents the company's most important strategic differentiator. Since 2022, Surgery Partners has opened 20 de novo facilities, with eight launched in 2025 and another nine under construction. These facilities are heavily weighted towards higher acuity specialties such as orthopedics and are typically purpose-built to capture cases migrating from hospital outpatient departments. The typical 12-18 month construction timeline plus another year to reach breakeven means these investments have a 2-3 year payback period, creating a capital deployment lag that investors must factor into growth expectations. However, once mature, these facilities offer substantially higher margins than acquired assets and allow Surgery Partners to reset discussions with payers from a position of strength.
Physician recruitment serves as the critical engine for organic growth. The company added nearly 700 physicians in 2025, with the Q1 recruiting class skewing toward orthopedic-focused positions that bring higher acuity cases. Doctors recruited in the first half of 2024 brought 68% more cases and 121% more revenue in the first half of 2025. This maturation curve demonstrates the compounding value of physician relationships, but it also explains the Q4 2025 shortfall—newer physicians initially serve a higher proportion of Medicare patients, creating temporary payer mix deterioration that should improve as they build their practices.
The portfolio optimization strategy, initiated in 2025, represents a proactive shift to accelerate balance sheet improvement. Management is evaluating a small number of larger surgical hospitals that fall outside of the core short-stay surgical strategy for potential partnership or divestiture. The Baylor Scott & White joint venture in Bryan, Texas, serves as the template: while the facility will be deconsolidated, earnings contribution is expected to improve due to a more efficient capital structure and strategic alignment. This approach allows Surgery Partners to reduce finance lease obligations and leverage while maintaining exposure to attractive markets through minority ownership.
Financial Performance & Segment Dynamics: Margin Compression Meets Capital Discipline
Surgery Partners' 2025 financial results show momentum in the first six months giving way to headwinds in the second half. Full-year net revenue of $3.31 billion grew 6.2% year-over-year, with same-facility revenue growth of 4.9% driven by 3.4% case volume growth and 1.4% revenue per case increase. However, adjusted EBITDA of $526 million grew only 3.5%, resulting in 40 basis points of margin compression to 15.9%. This divergence between revenue and profit growth signals that cost structures didn't adjust quickly enough to changing market conditions, particularly in the three surgical hospital markets that experienced physician transitions.
The Q4 2025 deterioration was notable. Same-facility case growth slowed to 1.3%, while payer mix shifted toward Medicare as experienced physicians with higher commercial payer mixes departed. In these affected markets, cost structures including labor and anesthesia coverage did not adjust quickly enough to that changing payer mix, creating incremental near-term margin pressure. This dynamic reveals a critical operational inflexibility: anesthesia costs and staffing levels are relatively fixed in the short term, but revenue per case can drop materially when commercial cases are replaced by lower-reimbursing Medicare cases. The result was fourth-quarter margins below the revised outlook, demonstrating how quickly localized physician issues can impact financial results.
Segment performance shows the strategic logic behind the portfolio pivot. The Surgical Facilities segment represents 97.5% of revenue at $3.31 billion, with ancillary services and management fees contributing the remainder. Within surgical facilities, the case mix shift toward orthopedics and GI procedures continued, with orthopedic cases growing 3.4% in Q1 to over 29,000 and total joint procedures growing 22%. However, GI procedure growth, while strong, pressured same-facility rates because these lower-acuity cases carry lower reimbursement. This mix effect reduced same-facility rate metrics by approximately 1% in Q1, illustrating the balance between volume growth and pricing power.
Cash flow performance reflects the capital-intensive nature of the de novo strategy. Operating cash flow was $274.3 million for 2025, down $25.8 million from 2024 due to working capital timing. Free cash flow of $195.6 million represents a 6.0% FCF margin. The company deployed $182 million in acquisitions during 2025 while opening eight de novos, demonstrating a dual-track capital deployment strategy. However, net cash used in investing activities decreased by $242 million year-over-year due to lower acquisition payments and higher proceeds from facility sales, indicating a deliberate shift toward organic development over M&A.
The balance sheet reflects the current leverage position. As of December 31, 2025, Surgery Partners had $3.7 billion in aggregate principal amount of indebtedness outstanding, including $1.4 billion in senior secured term loans and $1.225 billion in senior unsecured notes due 2032. The net leverage ratio was 4.2x at Q3 2025, with management targeting the 3x range over time. The expiration of $1.2 billion in interest rate swaps on March 31, 2025, created a headwind, replacing a 2.2% cap with deferred premium caps limiting the variable rate to 5%. This shift increased the effective interest rate to 7.4% in Q2 2025, adding $23 million in interest expense compared to Q2 2024. With $239.9 million in cash and $692.8 million in revolver capacity, liquidity is adequate but the interest burden consumes nearly 30% of EBITDA.
Outlook, Management Guidance, and Execution Risk
Management's 2026 guidance reflects a measured approach that incorporates the anticipated near-term impact of the headwinds discussed throughout 2025. The company projects net revenue of $3.3 billion to $3.45 billion, representing single-digit year-over-year growth, and adjusted EBITDA of "at least $530 million," implying minimal growth of 0.7% over 2025's $526 million. This guidance signals that management expects the physician transition issues and payer mix pressures to persist through much of 2026, with improvement only coming as newer physicians mature within the platform.
The guidance methodology reveals a shift in assumptions. The Q3 2025 guidance revision cut EBITDA by $20 million, with approximately 60% attributed to delayed capital deployment and lost earnings from divested ASCs, and 40% from cautious commercial payer mix and volume assumptions. This breakdown shows that execution issues outweighed fundamental market deterioration, suggesting the problems are addressable. Furthermore, the decision to exclude unannounced M&A from guidance indicates management recognizes the difficulty in predicting acquisition timing.
Management's commentary on physician maturation provides a timeline for recovery. Based on prior recruiting classes, physicians recruited in the first half of 2024 delivered 68% more cases and 121% more revenue in the first half of 2025. Applying this trajectory to the nearly 700 physicians added in 2025 suggests an acceleration in case volumes and commercial payer mix by late 2026 and into 2027. This frames the investment thesis around a 12-18 month execution window where margins may remain pressured before the de novo pipeline and physician maturation drive EBITDA growth.
The portfolio optimization strategy's timeline remains a focus for investors. Management indicated a comprehensive update would be provided at an upcoming Investor Day, aligned with a validating milestone in the portfolio optimization process. The Baylor Scott & White transaction provides a template: lower ownership but improved earnings contribution, suggesting the strategy prioritizes quality over quantity.
Risks and Asymmetries: What Could Break the Thesis
The physician transition risk represents the most immediate threat to the investment case. The Q4 2025 experience demonstrated that the loss of experienced physicians in concentrated markets can drive payer mix deterioration faster than cost structures can adjust, creating margin compression. This risk exposes the fundamental fragility of the physician partnership model—while alignment creates growth, dependence creates vulnerability. If recruitment quality declines or competitive pressures from hospitals and other ASC operators intensify, the 700 physicians added in 2025 may not mature as quickly as historical cohorts, delaying the anticipated margin recovery.
Payer mix shifts represent a systemic risk that could impact the portfolio optimization benefits. The expiration of Affordable Care Act subsidies on December 31, 2025, is anticipated to result in increases in premiums, potentially leading to decreased enrollment and a shift of individuals from commercial coverage to government program coverage in 2026. This matters because Surgery Partners derives 52.3% of revenue from private insurance, and any shift toward government payers would pressure rates further. The company's limited participation in Medicaid and exchange-based programs provides some insulation, but legislative changes to federal Medicaid expenditures could still increase uncompensated care and bad debt.
Leverage remains a constraint that limits strategic optionality. With $3.7 billion in debt and a net leverage ratio of 4.2x, Surgery Partners has minimal cushion against operational setbacks. The interest rate environment has already increased cash interest expense by $23 million annually, and any further rate increases would directly reduce free cash flow available for de novo development. The de novo pipeline is essential for long-term growth, but debt service consumes nearly 30% of EBITDA, forcing the company to balance growth investment and deleveraging. A failure to reach the targeted 3x leverage ratio by 2026 could limit access to capital for future acquisitions.
Regulatory changes, while generally favorable, carry execution risk. CMS's proposal to add 276 procedures to the ASC list and phase out the inpatient-only list over three years expands the addressable market, but Surgery Partners must invest in robotics, training, and physician recruitment to capture these procedures. The capital required to service this expanded market may strain the balance sheet, and competitors like HCA and Tenet have deep resources to move quickly. If Surgery Partners cannot deploy capital fast enough, it risks losing share in the highest-acuity, highest-margin procedures to better-capitalized rivals.
Valuation Context: Discounted for Execution Risk
At $12.26 per share, Surgery Partners trades at an enterprise value of $5.39 billion, representing 8.2x trailing EBITDA and 1.63x revenue. These multiples compare to HCA Healthcare (9.9x EV/EBITDA, 2.03x revenue) and Tenet Healthcare (6.1x EV/EBITDA, 1.33x revenue), with the discount reflecting Surgery Partners' smaller scale, higher leverage, and recent execution challenges. The price-to-free-cash-flow ratio of 8.1x appears attractive relative to the healthcare services sector, but this metric is influenced by the company's minimal cash taxes and may not be sustainable if working capital trends reverse.
The balance sheet metrics reveal the leverage position. With debt-to-equity of 1.15x and a current ratio of 1.87x, Surgery Partners has adequate liquidity but limited financial flexibility. The negative profit margin of -2.35% reflects integration costs and acquisition accounting, but the operating margin of 15.1% trails HCA's 16.3% and Tenet's 17.5%, indicating scale disadvantages. Return on assets of 3.74% and return on equity of 2.76% lag major competitors, demonstrating that the capital deployed in acquisitions and de novos has not yet generated its full potential returns.
Valuation must be considered in the context of the portfolio optimization strategy. If management successfully divests non-core surgical hospitals and redeploys capital into higher-margin ASCs, the EV/EBITDA multiple could contract toward 7x on improved earnings, creating 15-20% upside even without multiple expansion. However, if physician transition issues persist and de novo facilities fail to achieve breakeven on schedule, EBITDA could stagnate at $530 million, leaving the stock range-bound. The key variable is the pace of deleveraging: each 0.5x reduction in leverage could justify a 0.5x turn of multiple expansion.
Conclusion: A Show-Me Story with Asymmetric Risk/Reward
Surgery Partners' investment thesis hinges on the successful execution of a strategic pivot toward a pure-play ASC model while navigating the operational headwinds exposed by the Q4 2025 physician transition issues. The company's position as the last independent short-stay surgical provider offers strategic optionality with payers and physicians, and the regulatory tailwinds from CMS create a favorable market backdrop. However, the leverage position at 4.2x EBITDA, combined with the 220 basis point interest rate headwind and the timeline for de novo facilities to mature, creates a capital allocation challenge that management must solve through disciplined portfolio optimization.
The asymmetric risk/reward profile is defined by two scenarios. In the upside case, the nearly 700 physicians recruited in 2025 mature as expected, driving case volume growth above 5% and commercial payer mix improvement by late 2026. Successful divestiture of 3-5 surgical hospitals could reduce leverage to the upper 3s while improving margins, justifying multiple expansion toward 9x EBITDA and a stock price of $16-18. In the downside case, physician retention deteriorates further, payer mix shifts accelerate due to ACA subsidy expiration, and de novo facilities face construction delays or slower ramp-up, leaving EBITDA flat at $530 million and the stock vulnerable to a multiple compression to 6x EBITDA, implying downside to $9-10 per share.
The critical variable to monitor is management's execution on portfolio optimization. The Baylor Scott & White transaction provides a template for value creation through strategic partnerships, but investors require visibility into which assets are being evaluated and the expected timeline for completion. Until management provides this clarity at the promised Investor Day, SGRY remains a show-me story where the discount to larger peers like HCA and Tenet reflects legitimate execution risk. For investors willing to underwrite the physician maturation curve and management's capital allocation discipline, the current valuation offers meaningful upside, but any further operational stumbles could pressure the stock toward its 52-week lows as leverage concerns resurface.
